Citizen Petition from Attorney General of Massachusetts, et al.

Physicians for Reproductive Health, a physician-led national advocacy organization, supports the citizen petitions requesting the FDA eliminate restrictions on mifepristone access. They argue that mifepristone is safe and effective for medication abortion and miscarriage management, and that current restrictions—particularly those requiring in-person dispensing—unnecessarily create barriers to care and harm the patient-provider relationship.

The Boston University School of Law, through several of its legal programs, submits a supplemental comment supporting the removal of the Mifepristone Shared System Risk Evaluation and Mitigation Strategy (REMS). They argue that restricting access to mifepristone increases intimate partner violence (IPV) and imposes significant social and economic burdens, particularly on marginalized and low-income communities.

Legal Voice, Family Violence Appellate Project, Sexual Violence Law Center, and the Washington State Coalition Against Domestic Violence are submitting a joint comment in support of the petition to remove or relax the FDA's Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. They argue that the current restrictions create significant barriers to medication abortion, particularly for survivors of intimate partner violence (IPV) who face coercive control and need safe, private access to reproductive healthcare.

The Reproductive Health Outcomes and Disparities (RHOADs) Research Lab at the University of Chicago submitted this comment in support of the citizen petitions. They argue that the FDA should remove the mifepristone REMS or refrain from further restricting access, citing research that shows such regulations create significant barriers to care and lead to adverse maternal, infant, and socio-economic outcomes.

The Catholic Medical Association (CMA) opposes the proposed action, arguing that it expands access to chemical abortions which they believe are ethically wrong and medically risky. They advocate for stricter regulations, including mandatory in-person physician consultations, comprehensive informed consent regarding risks and alternatives, and reporting of all adverse effects.

Heartbeat International, Inc., a nonprofit organization providing pregnancy resources, opposes the petition from the Massachusetts Attorney General and other states to maintain relaxed regulations on mifepristone. The organization argues that the FDA should instead strengthen the Risk Evaluation and Mitigation Strategy (REMS) by reinstating in-person dispensing, mandatory adverse event reporting, and ultrasound requirements to ensure patient safety and informed consent.